One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision

Abstract Safety of the intravitreal plasma kallikrein inhibitor (KVD001) was tested in patients with diabetic macular edema. KVD001 was well tolerated. Systemic absorption was low. Improvement of retinal edema and vision occurred in most study eyes.